Cargando…

Delamanid Coadministered with Antiretroviral Drugs or Antituberculosis Drugs Shows No Clinically Relevant Drug-Drug Interactions in Healthy Subjects

Delamanid is a medicinal product approved for treatment of multidrug-resistant tuberculosis. Three studies were conducted to evaluate the potential drug-drug interactions between delamanid and antiretroviral drugs, including ritonavir, a strong inhibitor of CYP3A4, and selected anti-TB drugs, includ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mallikaarjun, Suresh, Wells, Charles, Petersen, Carolyn, Paccaly, Anne, Shoaf, Susan E., Patil, Shiva, Geiter, Lawrence
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2016
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5038266/ https://www.ncbi.nlm.nih.gov/pubmed/27458223 http://dx.doi.org/10.1128/AAC.00509-16

Ejemplares similares

Population Pharmacokinetics of Delamanid and its Main Metabolite DM-6705 in Drug-Resistant Tuberculosis Patients Receiving Delamanid Alone or Coadministered with Bedaquiline
por: Tanneau, Lénaïg, et al.
Publicado: (2022)

Early experience of delamanid in extensively drug-resistant pulmonary tuberculosis
por: Marwah, Vikas, et al.
Publicado: (2023)

Population Pharmacokinetic Analysis of Delamanid in Patients with Pulmonary Multidrug-Resistant Tuberculosis
por: Wang, Xiaofeng, et al.
Publicado: (2020)

The role of delamanid in the treatment of drug-resistant tuberculosis
por: Lewis, Joseph M, et al.
Publicado: (2015)

Cumulative Fraction of Response for Once- and Twice-Daily Delamanid in Patients with Pulmonary Multidrug-Resistant Tuberculosis
por: Mallikaarjun, Suresh, et al.
Publicado: (2020)

Long-term mortality assessment of multidrug-resistant tuberculosis patients treated with delamanid
por: Wells, Charles D., et al.
Publicado: (2015)

Acquired Resistance to Antituberculosis Drugs
por: Aung, Htin Lin, et al.
Publicado: (2018)

A Semimechanistic Pharmacokinetic Model for Depot Medroxyprogesterone Acetate and Drug–Drug Interactions With Antiretroviral and Antituberculosis Treatment
por: Francis, Jose, et al.
Publicado: (2021)

Advances of new drugs bedaquiline and delamanid in the treatment of multi-drug resistant tuberculosis in children
por: Zhu, Hanzhao, et al.
Publicado: (2023)

Delamanid: A new armor in combating drug-resistant tuberculosis
por: Xavier, Alphienes Stanley, et al.
Publicado: (2014)

Delamanid expanded access novel treatment of drug resistant tuberculosis
por: Rustomjee, Roxana, et al.
Publicado: (2015)

Antituberculosis drug-induced hepatotoxicity in children
por: Donald, Peter R
Publicado: (2011)

Diagnosis of Hypersensitivity Induced by Antituberculosis Drugs
por: Wu, Yuqing, et al.
Publicado: (2021)

Potential therapeutic hazards due to drug–drug interaction between topically and systemically coadministered medications
por: Lan, Mei-Juan, et al.
Publicado: (2013)

Antituberculosis Drug-Induced Fixed Drug Eruption: A Case Report
por: Vaghela, Jitendra H., et al.
Publicado: (2018)

Delamanid expanded access novel treatment of drug resistant tuberculosis [Corrigendum]
Publicado: (2016)

SAT-140 A Drug-Drug Interaction Trial of Oral Semaglutide with Levothyroxine and Multiple Coadministered Tablets
por: Hauge, Camilla, et al.
Publicado: (2019)

Mycobacterium tuberculosis resistance to antituberculosis drugs in Mozambique,
por: Pires, Germano Manuel, et al.
Publicado: (2014)

Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis
por: Skripconoka, Vija, et al.
Publicado: (2013)

Population Pharmacokinetic and Concentration-QTc Analysis of Delamanid in Pediatric Participants with Multidrug-Resistant Tuberculosis
por: Sasaki, Tomohiro, et al.
Publicado: (2022)

New developments in the treatment of drug-resistant tuberculosis: clinical utility of bedaquiline and delamanid
por: Brigden, Grania, et al.
Publicado: (2015)

The anti-tubercular drug delamanid as a potential oral treatment for visceral leishmaniasis
por: Patterson, Stephen, et al.
Publicado: (2016)

First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline
por: Tadolini, Marina, et al.
Publicado: (2016)

Natural Polymorphisms in Mycobacterium tuberculosis Conferring Resistance to Delamanid in Drug-Naive Patients
por: Reichmuth, Martina L., et al.
Publicado: (2020)

A concise and sequential synthesis of the nitroimidazooxazole based drug, Delamanid and related compounds
por: Sharma, Sumit, et al.
Publicado: (2020)

Bedaquiline, Delamanid, Linezolid, and Clofazimine for Treatment of Pre-extensively Drug-Resistant Tuberculosis
por: Padmapriyadarsini, Chandrasekaran, et al.
Publicado: (2022)

Therapeutic Failure and Acquired Bedaquiline and Delamanid Resistance in Treatment of Drug-Resistant TB
por: Millard, James, et al.
Publicado: (2023)

Adverse Reactions to Antituberculosis Drugs in Iranian Tuberculosis Patients
por: Farazi, Aliasghar, et al.
Publicado: (2014)

Risk factors associated with adverse reactions to antituberculosis drugs
por: Resende, Laíse Soares Oliveira, et al.
Publicado: (2015)

Seizures following Intoxication with a Common Antituberculosis Drug
por: Lahlou, Adnane, et al.
Publicado: (2019)

Aureolic Acid Group of Agents as Potential Antituberculosis Drugs
por: Bespyatykh, Julia, et al.
Publicado: (2020)

Epidemiology of tuberculosis and susceptibility to antituberculosis drugs in Reunion Island
por: Loukman, Moreea, et al.
Publicado: (2023)

Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis
por: Maryandyshev, Andrey, et al.
Publicado: (2017)

Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Children: The Role of Bedaquiline and Delamanid
por: Pecora, Francesco, et al.
Publicado: (2021)

The drug interaction potential of daprodustat when coadministered with pioglitazone, rosuvastatin, or trimethoprim in healthy subjects
por: Caltabiano, Stephen, et al.
Publicado: (2018)

New Antituberculosis Drugs: From Clinical Trial to Programmatic Use
por: Gualano, Gina, et al.
Publicado: (2016)

Association of PXR and CAR Polymorphisms and Antituberculosis Drug-Induced Hepatotoxicity
por: Wang, Yu, et al.
Publicado: (2019)

Adverse drug reaction profile of daily regimen antituberculosis treatment
por: Sankar, K. N. Hari, et al.
Publicado: (2022)

Clinical impact of plasma concentrations of first-line antituberculosis drugs
por: Perumal, R, et al.
Publicado: (2023)

Clinically Relevant Transmitted Drug Resistance to First Line Antiretroviral Drugs and Implications for Recommendations
por: Monge, Susana, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_i3pmj3i14vukq44lb5jvhd2tih